CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 56 enrolled
Drug / intervention
Change from Prograf to Envarsus XRdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04838288
NCT04838288Phase 4Completed
CompareCT.gov

Cognitive Outcomes and Quality of Life in Stable Renal Transplant Patients Switched fromTwice-Daily Tacrolimus to Envarsus XR™

Vanderbilt University Medical Center·interventional·Posted Apr 9, 2021·Updated Apr 29, 2026

In Brief

A Phase 4 clinical trial evaluating Change from Prograf to Envarsus XR for Renal Transplant. Completed, enrolled 56 participants across 1 site.

Detailed Summary

The purpose of this study is to assess cognitive outcome and quality of life in stable renal transplant patients treated with twice daily tacrolimus at baseline and after switching to Envarsus XL. The study is designed to see if switching patients from Tacrolimus to Envarsus treatment improves cognitive function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplant
CountriesUnited States
CollaboratorsVeloxis Pharmaceuticals

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedApr 9, 2021
Enrollment StartJun 22, 2021
Primary CompletionJan 1, 2025
Study CompletionOct 22, 2025
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 5.2 years ago

Interventions

Change from Prograf to Envarsus XRdrug

Change from Tacrolimus taken twice a day to Envarsus XR taken once a day